Article: Nicotinamide Riboside Supplementation Raises NAD+ and Lowers Alzheimer's-Associated Biomarkers: Clinical Findings

Dec 14, 2022 Clinical Neurological Health

Nicotinamide Riboside Supplementation Raises NAD+ and Lowers Alzheimer's-Associated Biomarkers: Clinical Findings

Objectives

To evaluate if NR could augment neuronal NAD+ levels and impact markers of neurodegeneration and insulin-signaling in plasma-derived human neuronal extracellular vesicles (NEVs).

Journal

Aging Cell

Key Outcomes

NR supplementation significantly increased NAD+ in plasma derived human neuronal extracellular vesicles (NEVs), suggesting an increase in neuronal NAD+ levels.
In NEVs, NR also decreased levels of Aβ42, an Alzheimer's disease biomarker, as well as biomarkers pJNK and pERK1/2, which are involved in insulin resistance and neuroinflammatory pathways.

Duration

6 weeks

Dose

1000 mg

Study Design

Randomized, double-blind, placebo-controlled, crossover study in 22 healthy, middle-aged and older men and women

See Published Study

Depression

Nicotinamide Riboside Improved Mood and Behavior in Depression: Preclinical Findings

Synopsis This study found that low levels of NAD+, a molecule essential for brain energy and cell function, may contribute to depression-like symptoms. Mice with reduced activity of the enzyme NAM...

Alzheimer's Disease

Combined Metabolic Activators Including Nicotinamide Riboside Improve Metabolism in Alzheimer's and Parkinson's Disease: Preclinical Findings

Synopsis Neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD) are linked to metabolic problems, including mitochondrial dysfunction. This study analyzed human brai...